DCM
GNMK

Delpha Capital Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Delpha Capital Management’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-267
Closed -$1K – 1478
2017
Q4 		$1K Buy
+267
New +$1.61K ﹤0.01% 1618

Other funds holding GNMK

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Delpha Capital Management's GNMK Position: Q1 2018 in Review

Delpha Capital Management sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2018, closing a stake of 267 shares — an estimated $1K sold.

Delpha Capital Management first reported a position in GNMK in Q4 2017 and held it in 1 quarter. The position peaked at $1K in Q4 2017. 98 funds tracked by Wall St. Rank hold GNMK as of Q1 2018.

  • Delpha Capital Management reported no remaining GenMark Diagnostics, Inc position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 267 GenMark Diagnostics, Inc shares in Q1 2018, an estimated $1K.
  • Delpha Capital Management first reported a position in GenMark Diagnostics, Inc in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's GenMark Diagnostics, Inc position peaked at $1K in Q4 2017.
  • 98 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.